Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Clinical trial NCT03868423 · WITHDRAWN

Trial details

NCT number: NCT03868423
Sponsor: Sameek Roychowdhury
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Neoplasm ALK Fusion Protein Expression ALK Gene Amplification ALK Gene Mutation Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Neoplasm in the Brain Metastatic Malignant Neoplasm in the Central Nervous System Metastatic Malignant Solid Neoplasm ROS1 Fusion Positive ROS1 Gene Amplification ROS1 Gene Mutation

Start date: 2019-03-20
Primary completion: 2020-11-20
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.